Simple Summary Multigene testing in ovarian cancer has received increased support due to
its 'applicability for cancer treatment and the impact it has on cancer prevention in families …

Ovarian cancer remains the most lethal gynaecological malignancy with 314 000 cases and
207 000 deaths annually worldwide. Ovarian cancer cases and deaths are predicted to …

National guidelines recommend testing all cases of non-mucinous epithelial ovarian cancer
(NMEOC) for germline (blood) and somatic (tumour) BRCA1/2 pathogenic variants (PVs) …

Simple Summary Ovarian cancer survival in the UK is poorer than other similar countries.
Results from the National Ovarian Cancer Audit Feasibility Pilot (OCAFP) showed that …

Recommendations are graded as per the Royal College of Obstetricians and
Gynaecologists document, Clinical Governance Advice No. 1: Guidance for the …

ASCO Guidelines provide recommendations with comprehensive review and analyses of
the relevant literature for each recommendation, following the guideline development …

Objective To determine the frequency of germline and somatic pathogenic BRCA1 and
BRCA2 variants in patients with high‐grade serous ovarian cancer tested by next …

Simple Summary Genotyping of BRCA genes is required for treatment with PARP inhibitors.
Purposing to address treatment needs and familial cancer risk, the aim of our study was to …

Universal tumor DNA testing in epithelial ovarian cancer patients can function not only as an
efficient prescreen for hereditary cancer testing, but may also guide treatment choices. This …

The evaluation of biomarkers by molecular techniques and immunohistochemistry has
become increasingly relevant to the treatment of female genital tract tumours as a …